The biopharma delivered the goods with its drug pipeline, scored marketing approval for its lead drug candidate, and agreed to be acquired for $8 billion.
News & Analysis: Loxo Oncology
These companies arguably stole the show at J.P. Morgan's high-profile healthcare conference this year.
These stocks skyrocketed following exciting announcements.
The big pharma agreed to pay $8 billion for drugs with uncertain futures.
Stocks advanced, with Eil Lilly buying Loxo Oncology and Sage Therapeutics reporting a clinical trial success.
Shares jumped more than 66% in response to news that the company is being acquired. Here's what investors need to know.
In some ways, this is the most exciting FDA approval of the year, but don't look for blockbuster sales.
Here's how shares of these drugmakers surged to nosebleed valuations.
With new drug applications under review at the moment, these 3 biotech stocks could surge in the weeks ahead.
This year's World Conference on Lung Cancer has some important presentations scheduled.